MRP2/ABCC2 C1515Y polymorphism modulates exposure to lumefantrine during artemether-lumefantrine antimalarial therapy.

about

The drug transporter ABCB1 c.3435C>T SNP influences artemether-lumefantrine treatment outcome.

P2860

Q41693100-F74E9C22-CB31-4846-A553-F4BFADC26041

P2860

MRP2/ABCC2 C1515Y polymorphism modulates exposure to lumefantrine during artemether-lumefantrine antimalarial therapy.

Item

http://www.wikidata.org/entity/Q36412071

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

MRP2/ABCC2 C1515Y polymorphism ...... fantrine antimalarial therapy.

@ast

MRP2/ABCC2 C1515Y polymorphism ...... fantrine antimalarial therapy.

@en

type

Item

label

MRP2/ABCC2 C1515Y polymorphism ...... fantrine antimalarial therapy.

@ast

MRP2/ABCC2 C1515Y polymorphism ...... fantrine antimalarial therapy.

@en

prefLabel

MRP2/ABCC2 C1515Y polymorphism ...... fantrine antimalarial therapy.

@ast

MRP2/ABCC2 C1515Y polymorphism ...... fantrine antimalarial therapy.

@en

P1476

MRP2/ABCC2 C1515Y polymorphism ...... fantrine antimalarial therapy.

@en

P2093

Andreas Mårtensson

http://www.w3.org/2001/XMLSchema#string

Billy Ngasala

http://www.w3.org/2001/XMLSchema#string

Carlotta Lo Sciuto

http://www.w3.org/2001/XMLSchema#string

José Pedro Gil

http://www.w3.org/2001/XMLSchema#string

Karin Vos

http://www.w3.org/2001/XMLSchema#string

Michael Ashton

http://www.w3.org/2001/XMLSchema#string

Rita Piedade

http://www.w3.org/2001/XMLSchema#string

P2860

A "silent" polymorphism in the MDR1 gene changes substrate specificity

Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria.

Population pharmacokinetics and pharmacodynamics of artemether and lumefantrine during combination treatment in children with uncomplicated falciparum malaria in Tanzania.

Effect of single nucleotide polymorphisms in cytochrome P450 isoenzyme and N-acetyltransferase 2 genes on the metabolism of artemisinin-based combination therapies in malaria patients from Cambodia and Tanzania.

Understanding the pharmacokinetics of Coartem.

Investigation of the functional role of P-glycoprotein in limiting the oral bioavailability of lumefantrine.

The pharmacogenetics of antimalaria artemisinin combination therapy.

Functional characterization of protein variants of the human multidrug transporter ABCC2 by a novel targeted expression system in fibrosarcoma cells.

Simplified antimalarial therapeutic monitoring: using the day-7 drug level?

Functional defect caused by the 4544G>A SNP in ABCC2: potential impact for drug cellular disposition.

P304

981-985

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/PGS-2017-0032

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Anders Björkman

P577

2017-06-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28639487

http://www.w3.org/2001/XMLSchema#string

P921

antimalarial

MRP2/ABCC2 C1515Y polymorphism modulates exposure to lumefantrine during artemether-lumefantrine antimalarial therapy.

about

P2860

P2860

MRP2/ABCC2 C1515Y polymorphism modulates exposure to lumefantrine during artemether-lumefantrine antimalarial therapy.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921